Fu Yu Corp doubles down on biomedical bet
Added capabilities enable it to value-add and engage new customers, as well as pursue further collaborations with existing customers
Add BT as a preferred source
PRECISION plastic parts manufacturer Fu Yu Corp aims to increase sales from its biomedical segment to more than half of the group’s revenue within the next three to five years, up from the current 3 per cent, supported by the launch of its smart factory and new product design capabilities.
“The 3 per cent is evidence that it’s there,” said group chief executive officer David Seow. “We haven’t moved the needle yet, because for some of the capabilities that we’ve got since last year, it takes time. But the signs are there.”
The global biomedical devices market reportedly reached about US$600 billion in 2023, and is expected to grow 6 to 7 per cent annually, Seow said. It is “clearly a sunrise industry”, compared with Fu Yu’s other sectors, such as printing and imaging, consumer, automotive, and medical (where it produces casings), he added.
TRENDING NOW
Two-thirds of Sentosa Cove resales in the red, with average loss topping S$1 million since 2023
Singapore at 61: How we can ensure opportunity, security and ownership for the next generation
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
